Grob and colleagues described the genetic background of 230 patients with TP53-mutated AML and high-risk MDS, among 2200 participants in the Haemato-Oncology Foundation for Adults in the Netherlands and Swiss Group for Clinical Cancer Research (HOVON-SAKK) clinical trials [161]. This evidence concerns the gene TP53 and acute myeloid leukemia.